A New Tool Against the Flu
The flu is more than just a bad cold. Each year, it sends thousands of people to the hospital and, sadly, can be deadly. That's why news of a new vaccine is always welcome. Recently, the U.S. Food and Drug Administration (FDA) approved a new flu vaccine from Moderna. It's called mFLUSIVA, and it's the first flu vaccine to use mRNA technology, the same kind used in some COVID-19 vaccines.
This new vaccine is approved for adults aged 50 and older. If you're in that age group, you might be wondering what this means for you. Let's break it down in simple terms.
What Is mFLUSIVA?
mFLUSIVA is a seasonal flu vaccine designed to protect against influenza. It uses messenger RNA (mRNA) to teach your body's cells to make a protein that triggers an immune response. This is different from traditional flu vaccines, which are often made using eggs.
The FDA approved mFLUSIVA based on a large phase 3 clinical trial that included more than 40,000 adults aged 50 and older across 11 countries. In that study, about half of the participants got mFLUSIVA, and the other half got a standard-dose licensed flu vaccine. The results showed that mFLUSIVA was better at preventing flu-like illness confirmed by lab tests.
For adults aged 65 and older, the vaccine received accelerated approval. This was based on a smaller study that looked at how well the vaccine triggered an immune response compared with a high-dose flu shot. Accelerated approval means the FDA wants more proof that the vaccine prevents serious outcomes like hospitalization in this age group.
Why Is This Approval Important?
The flu can be serious, especially for older adults. According to the Centers for Disease Control and Prevention (CDC), there were an estimated 45,000 flu-related deaths in the U.S. during the 2024-2025 flu season. Vaccination helped prevent around 12,000 of those deaths.
If mFLUSIVA turns out to be more effective than standard flu vaccines, it could help protect even more people. Dr. Dung Trinh, an internist not involved in the trials, called the approval “an important addition to our influenza prevention toolkit.” He noted that adults over 50 are at higher risk for serious flu complications.
Dr. David Cutler, a family medicine physician, was more cautious. He said the approval is “scientifically interesting and potentially important,” but he wouldn't say it's the best flu vaccine for every person over 50. He pointed out that the FDA gave full approval for ages 50-64, but only accelerated approval for 65 and older. That means we still need more data on how well it works in the oldest age group.
The Big Advantage: Speed
Flu viruses change constantly. By the time a traditional egg-based vaccine is made, which can take at least six months, the virus may have changed enough that the vaccine isn't a perfect match. That's a big problem because a mismatched vaccine can be less effective.
mRNA vaccines can be produced much faster. This means they can be updated more quickly to match the strains that are actually circulating. Dr. Cutler called this “a potentially important technological advantage.” It could help solve the perennial problem of vaccine-virus mismatch.
Is It More Effective?
Based on the trial data, yes, it might be more effective for some people. For adults aged 50-64, mFLUSIVA showed about 27% greater relative vaccine efficacy against confirmed flu compared with a standard-dose vaccine. That's a significant improvement.
However, Dr. Cutler reminded us that the real test is whether it prevents hospitalization, pneumonia, and death, especially in people 65 and older. Higher antibody levels don't always mean better protection in the real world.
What About Side Effects?
Like any vaccine, mFLUSIVA can cause side effects. The most common ones reported in trials include:
- Headache
- Fatigue
- Joint pain
- Muscle pain
- Nausea
- Vomiting
- Fever
- Chills
There were also reactions at the injection site, like soreness or redness. In rare cases, a severe allergic reaction (anaphylaxis) can occur. If you have a history of severe allergies, talk to your doctor before getting any vaccine.
When Will It Be Available?
Moderna expects mFLUSIVA to be available in the U.S. for the 2026-2027 respiratory virus season. That means you likely won't see it this year, but it's coming.
Should You Wait for It?
If you're 50 or older, you might be tempted to skip your flu shot this year and wait for mFLUSIVA. But experts advise against that. The flu can strike at any time, and the vaccines we have now are still your best protection until mFLUSIVA arrives. As Dr. Cutler said, this new vaccine is “not proof that the mRNA vaccine is necessarily the best flu vaccine for every person over 50.”
The best thing you can do is talk to your doctor about which flu vaccine is right for you. They can help you weigh the benefits and risks based on your health history.
The Future of Flu Vaccines
The approval of mFLUSIVA is a big step forward. It shows that mRNA technology can be used beyond COVID-19. If it works well, it could change how we respond to seasonal flu and even future pandemics. But for now, it's another option, not a replacement for existing vaccines.
Remember, the flu vaccine is recommended for everyone 6 months and older. Even if it's not perfect, it's one of the best ways to protect yourself and your loved ones. If you have questions, talk to a qualified healthcare provider.
Source: https://www.medicalnewstoday.c...